Taipei Exchange - Delayed Quote TWD

Enimmune corporation (6564.TWO)

16.85
0.00
(0.00%)
As of June 5 at 2:35:09 PM GMT+8. Market Open.

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Zhe Wei Zhang President -- -- --
You Kang Lin Accounting Supervisor -- -- --

Enimmune corporation

No. 3, Section 1
Tanxing Road Tanzi District
Taichung City
Taiwan
886 4 2536 0925 https://www.enimmune.com.tw
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectious diseases, such as enterovirus, pneumonia, norovirus, dengue fever virus, Middle East respiratory syndrome coronavirus, etc. Enimmune corporation was founded in 2014 and is based in Taichung City, Taiwan.

Corporate Governance

Enimmune corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers